ImmunoBiochem is an innovative biopharmaceutical company on a mission to develop novel bioconjugate therapeutics, such ADCs, ISACs and DACs, to address significant unmet need in oncology, immuno-oncology and immunology. In precision oncology and immuno-oncology, ImmunoBiochem is focused on the discovery of novel tumor secretome-based targets utilizing a combination of high-throughput functional assays, mass spectrometry and AI/ML to unravel unique cancer biology. In precision immunology, ImmunoBiochem’s novel bioconjugates utilize unique antibody targets for the delivery of potent protein degrader payloads modulating select immunological pathways in specific cell subtypes in the desirable context in relevant autoimmune disorders such as to avoid broad side-effects of existing biologics and small molecule therapeutics. ImmunoBiochem is a JLABS alumnus and is a revenue-generating biotech with biopharma and academic partnerships. ImmunoBiochem is headquartered in Ontario, Canada, and draws on the vast expertise of cancer researchers and clinicians located in the biomedical hub of downtown Toronto.
Something looks off?